EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales
LYON, France, January 8, 2024 – EDAP TMS SA (Nasdaq:EDAP), (“EDAP”), the global leader in robotic energy-based therapies, announced today preliminary Focal One placement results for the fourth quarter of calendar year 2023. The Company experienced robust demand for its Focal One robotic HIFU technology, placing twelve Focal One systems, inclusive of ten capital sales. Additionally, it was a record quarter for sales of ExactVu™ Micro-Ultrasound systems used for prostate biopsy. The breadth of these new Focal One and ExactVu placements continues to be strong, with growing interest amongst both academic medical centers and community hospitals.
Related news for (EDAP)
- EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
- EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
- EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
- EDAP Announces First Quarter 2023 Financial Results